Latest News for: nsclc

Edit

Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

PR Newswire 21 Mar 2026
The findings suggest that ZEGFROVY monotherapy has the potential to become the first and only chemo free, oral agent to treat newly diagnosed NSCLC patients with EGFR exon20ins ... for the treatment of relapsed or refractory NSCLC with EGFR exon20ins.
Edit

CHOSA: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress (Chosa Oncology AB)

Public Technologies 19 Mar 2026
CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress ... NSCLC.
Edit

CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress (Chosa Oncology AB)

Public Technologies 19 Mar 2026
) CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress.
Edit

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis (Form 6-K) (Immutep Ltd)

Public Technologies 16 Mar 2026
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis ... Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
Edit

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Nasdaq Globe Newswire 13 Mar 2026
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis ... .
Edit

NSCLC Clinical Trial Analysis 2026: 135+ Companies, 150+ Pipeline Therapies, 7+ Recent FDA Milestones Reshaping ...

GetNews 02 Mar 2026
Key Highlights from the NSCLC Pipeline Analysis The NSCLC pipeline reflects a highly competitive environment, with over 135 active organizations developing more than 150 novel therapies ... NSCLC Disease Overview.
Edit

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC

Hastings Tribune 26 Feb 2026
This press release is not intended for UK media ... .
Edit

FDA approves HERNEXEOS�, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an ...

Nasdaq Globe Newswire 26 Feb 2026
This press release is not intended for UK media ... .
Edit

CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

Morgan Citizen 23 Feb 2026
... for stage III non-small cell lung cancer (NSCLC).
Edit

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

PR Newswire 11 Feb 2026
EGFR-NSCLC Market Summary The market size for EGFR-NSCLC was found to be USD 6 billion in the leading markets in 2024 ... The total number of incident cases of EGFR-NSCLC in the leading market was nearly 117,000 in 2024 ... What is EGFR-NSCLC?.
Edit

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (Form 6-K) (Immutep Ltd)

Public Technologies 10 Feb 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC • ... Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
Edit

NSCLC Clinical Trial Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

GetNews 10 Feb 2026
DelveInsight’s "NSCLC Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape ... NSCLC Overview ... NSCLC Emerging Drugs Profile V940 ... NSCLC Companies.
Edit

EGFR + NSCLC Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ...

GetNews 09 Feb 2026
It covers the EGFR + NSCLC pipeline drug profiles, including clinical and nonclinical stage products ... Explore our latest breakthroughs in EGFR + NSCLC research ... Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments.
Edit

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Nasdaq Globe Newswire 06 Feb 2026
... and chemotherapy as first line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC).
Edit

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (Immutep Ltd)

Public Technologies 06 Feb 2026
) Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC ... Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).

Article Search

tools
×
×
×
×